AZD7442
- Generic Name
- AZD7442
- Drug Type
- Biotech
- Background
AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.
AZ's Antibody First to Be Cleared by FDA for COVID Prevention
AstraZeneca's antibody cocktail, Evusheld, has been authorized by the FDA for COVID-19 prevention in individuals with compromised immunity, marking a significant advancement in the fight against the pandemic.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath